<![CDATA[This study aim to evaluate the prescribing behavior in preeclampsia patients, evaluate the achievements of therapy, and analyze the safety of antihypertensive drugs in pregnant women based on the guidelines of the United States Food and Drug Administration (US FDA) and the Australian Therapeutic Goods Administration (AU TGA). This retrospective cohort study involved a total of 832 patients with preeclampsia at secondary hospitals in Yogyakarta, Indonesia. The data collection was conducted from 2018 to 2024. Analytical and descriptive methods were employed to examine both patient characteristics and treatment variables. This study record that the complete recommendation therapy for preeclampsia mother was dominantly received during the hospitalizations among all patients with 3rd trimester pregnancy (100%), and gravida state <3 (72.9%). Nifedipine exhibited the most significant rate of drug prescription among patients, with 526 (63.2%) patients falling into the safety class C category according to US FDA and AU TGA guidelines. This study highlights the efficacy of methyldopa monotherapy and dual therapy with nifedipine in achieving blood pressure targets among the preeclampsia patients. This study supports that methyldopa is the safest choice for preeclampsia, while nifedipine provides a reliable backup option, underscoring its effectiveness in lowering blood pressure among preeclampsia patients.]]>
Copyrights © 2026
